Urbanek Konrad, De Angelis Antonella, Spaziano Giuseppe, Piegari Elena, Matteis Maria, Cappetta Donato, Esposito Grazia, Russo Rosa, Tartaglione Gioia, De Palma Raffaele, Rossi Francesco, D'Agostino Bruno
Department of Experimental Medicine, Section of Pharmacology, Second University of Naples, Naples, Italy.
Department of Clinical and Experimental Medicine, Second University of Naples, Naples, Italy.
PLoS One. 2016 Jul 19;11(7):e0158746. doi: 10.1371/journal.pone.0158746. eCollection 2016.
The need for new options for chronic lung diseases promotes the research on stem cells for lung repair. Bone marrow-derived mesenchymal stem cells (MSCs) can modulate lung inflammation, but the data on cellular processes involved in early airway remodeling and the potential involvement of neuropeptides are scarce.
To elucidate the mechanisms by which local administration of MSCs interferes with pathophysiological features of airway hyperresponsiveness in an animal model.
GFP-tagged mouse MSCs were intratracheally delivered in the ovalbumin mouse model with subsequent functional tests, the analysis of cytokine levels, neuropeptide expression and histological evaluation of MSCs fate and airway pathology. Additionally, MSCs were exposed to pro-inflammatory factors in vitro.
Functional improvement was observed after MSC administration. Although MSCs did not adopt lung cell phenotypes, cell therapy positively affected airway remodeling reducing the hyperplastic phase of the gain in bronchial smooth muscle mass, decreasing the proliferation of epithelium in which mucus metaplasia was also lowered. Decrease of interleukin-4, interleukin-5, interleukin-13 and increase of interleukin-10 in bronchoalveolar lavage was also observed. Exposed to pro-inflammatory cytokines, MSCs upregulated indoleamine 2,3-dioxygenase. Moreover, asthma-related in vivo upregulation of pro-inflammatory neurokinin 1 and neurokinin 2 receptors was counteracted by MSCs that also determined a partial restoration of VIP, a neuropeptide with anti-inflammatory properties.
Intratracheally administered MSCs positively modulate airway remodeling, reduce inflammation and improve function, demonstrating their ability to promote tissue homeostasis in the course of experimental allergic asthma. Because of a limited tissue retention, the functional impact of MSCs may be attributed to their immunomodulatory response combined with the interference of neuropeptide system activation and tissue remodeling.
慢性肺部疾病对新治疗方案的需求推动了用于肺修复的干细胞研究。骨髓间充质干细胞(MSCs)可调节肺部炎症,但关于早期气道重塑所涉及的细胞过程以及神经肽潜在参与情况的数据较少。
阐明在动物模型中局部给予MSCs干预气道高反应性病理生理特征的机制。
在卵清蛋白小鼠模型中经气管内递送绿色荧光蛋白标记的小鼠MSCs,随后进行功能测试、细胞因子水平分析、神经肽表达分析以及对MSCs命运和气道病理的组织学评估。此外,在体外使MSCs暴露于促炎因子。
给予MSCs后观察到功能改善。尽管MSCs未呈现肺细胞表型,但细胞治疗对气道重塑产生了积极影响,减少了支气管平滑肌质量增加的增生期,降低了上皮细胞增殖,其中黏液化生也有所降低。还观察到支气管肺泡灌洗中白细胞介素-4、白细胞介素-5、白细胞介素-13减少以及白细胞介素-10增加。暴露于促炎细胞因子时,MSCs上调吲哚胺2,3-双加氧酶。此外,MSCs抵消了体内哮喘相关的促炎神经激肽1和神经激肽2受体上调,还使具有抗炎特性的神经肽血管活性肠肽(VIP)部分恢复。
经气管内给予的MSCs对气道重塑产生积极调节作用,减轻炎症并改善功能,表明它们在实验性过敏性哮喘过程中促进组织稳态的能力。由于组织滞留有限,MSCs的功能影响可能归因于其免疫调节反应以及对神经肽系统激活和组织重塑的干扰。